

## South East Regional Medicines Optimisation Group (SERMOG) policy recommendation

<b>Title:</b>	Dual biological therapy for inflammatory bowel disease in adults
<b>Number:</b>	SERMOG-01
<b>Category:</b>	Not normally funded
<b>Date determined by SERMOG:</b>	July 2024

<b>Policy recommendation:</b>
<p>The South East Regional Medicines Optimisation Group (SERMOG) considered national guidance, the evidence base, baseline position, other integrated care board (ICB) policies, the views of clinical specialists, equality and equity issues, and the potential impact of changing policy.</p> <p>All decisions were made with reference to the South East Region Policy Recommendation Committees' Ethical Framework. Taking these into account, the SERMOG recommends:</p> <ul style="list-style-type: none"> <li>• Dual biological therapy* is not normally funded for the treatment of inflammatory bowel disease (IBD) in adults.</li> </ul> <p><i>*Including treatment combinations of biological drugs and small molecules (JAK inhibitors and sphingosine-1-phosphate receptor modulators).</i></p> <p><b>Policy exclusions</b></p> <ul style="list-style-type: none"> <li>• Patients aged under 18; NHS England are responsible for commissioning biologicals for IBD in children.</li> </ul>
<b>Version control:</b>
Final version 1.0 – Circulated to ICBs for ratification on 8 August 2024
<b>Notes:</b>
<p>This policy recommendation will be reviewed when new information becomes available that is likely to have a material effect on the current recommendation.</p> <p>NHS Buckinghamshire, Oxfordshire and Berkshire West ICB; NHS Frimley ICB; NHS Hampshire and Isle of Wight ICB; NHS Kent and Medway ICB; NHS Sussex ICB and NHS Surrey Heartlands ICB will always consider appropriate individual funding requests (IFRs) through their IFR processes.</p>